28069279|t|Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study
28069279|a|Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safety and efficacy of masitinib versus placebo in severely symptomatic patients who were unresponsive to optimal symptomatic treatments. In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on histological criteria, at 50 centres in 15 countries. We excluded patients with cutaneous or non-severe systemic mastocytosis after a protocol amendment. Patients were centrally randomised (1:1) to receive either oral masitinib (6 mg/kg per day over 24 weeks with possible extension) or matched placebo with minimisation according to severe symptoms. The primary endpoint was cumulative response (≥75% improvement from baseline within weeks 8-24) in at least one severe baseline symptom from the following: pruritus score of 9 or more, eight or more flushes per week, Hamilton Rating Scale for Depression of 19 or more, or Fatigue Impact Scale of 75 or more. We assessed treatment effect using repeated measures methodology for rare diseases via the generalised estimating equation model in a modified intention-to-treat population, including all participants assigned to treatment minus those who withdrew due to a non-treatment-related cause. We assessed safety in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT00814073. Between Feb 19, 2009, and July 15, 2015, 135 patients were randomly assigned to masitinib (n=71) or placebo (n=64). By 24 weeks, masitinib was associated with a cumulative response of 18·7% in the primary endpoint (122·6 responses of 656·5 possible responses [weighted generalised estimating equation]) compared with 7·4% for placebo (48·9 of 656·5; difference 11·3%; odds ratio 3·6; 95% CI 1·2-10·8; p=0·0076). Frequent severe adverse events (>4% difference from placebo) were diarrhoea (eight [11%] of 70 in the masitinib group vs one [2%] of 63 in the placebo group), rash (four [6%] vs none), and asthenia (four [6%] vs one [2%]). The most frequent serious adverse events were diarrhoea (three patients [4%] vs one [2%]) and urticaria (two [3%] vs none), and no life-threatening toxicities occurred. One patient in the placebo group died (unrelated to study treatment). These study findings indicate that masitinib is an effective and well tolerated agent for the treatment of severely symptomatic indolent or smouldering systemic mastocytosis. AB Science (Paris, France).
28069279	0	9	Masitinib	T109,T121	C2351398
28069279	14	23	treatment	T061	C0087111
28069279	27	35	severely	T080	C0205082
28069279	36	47	symptomatic	T169	C0231220
28069279	48	78	indolent systemic mastocytosis	T047	C0272203
28069279	82	92	randomised	T062	C0034656
28069279	94	112	placebo-controlled	T062	C1706408
28069279	114	127	phase 3 study	T062	C0282461
28069279	128	158	Indolent systemic mastocytosis	T047	C0272203
28069279	174	184	subvariant	T080	C0205556
28069279	188	221	smouldering systemic mastocytosis	T191	C3897042
28069279	228	236	lifelong	T079	C4274169
28069279	247	262	associated with	T080	C0332281
28069279	263	286	reduced quality of life	T033	C1963786
28069279	288	297	Masitinib	T109,T121	C2351398
28069279	298	306	inhibits	T052	C3463820
28069279	307	310	KIT	T116,T126	C0033640
28069279	315	326	LYN kinases	T116,T126	C1442804
28069279	348	378	indolent systemic mastocytosis	T047	C0272203
28069279	379	391	pathogenesis	T046	C0699748
28069279	412	418	safety	T062	C1705187
28069279	423	431	efficacy	T062	C1707887
28069279	435	444	masitinib	T109,T121	C2351398
28069279	452	459	placebo	T122	C1696465
28069279	463	483	severely symptomatic	T033	C0436345
28069279	484	492	patients	T101	C0030705
28069279	502	514	unresponsive	T169	C0205269
28069279	518	525	optimal	T080	C2698651
28069279	526	537	symptomatic	T169	C0231220
28069279	538	548	treatments	T061	C0087111
28069279	558	568	randomised	T062	C0034656
28069279	570	582	double-blind	T062	C0013072
28069279	584	602	placebo-controlled	T062	C1706408
28069279	604	617	phase 3 study	T062	C0282461
28069279	631	637	adults	T100	C0001675
28069279	639	643	aged	T032	C0001779
28069279	662	670	indolent	T047	C0272203
28069279	674	707	smouldering systemic mastocytosis	T191	C3897042
28069279	722	725	WHO	T093	C0043237
28069279	726	740	classification	T185	C0008902
28069279	744	754	documented	T170	C0920316
28069279	755	767	mastocytosis	T047	C0024899
28069279	777	798	histological criteria	T201	C0449574
28069279	820	829	countries	T083	C0454664
28069279	843	851	patients	T101	C0030705
28069279	857	866	cutaneous	T082	C0221912
28069279	881	902	systemic mastocytosis	T047	C0221013
28069279	911	929	protocol amendment	T170	C1507394
28069279	931	939	Patients	T101	C0030705
28069279	955	965	randomised	T062	C0034656
28069279	990	994	oral	T169	C1527415
28069279	995	1004	masitinib	T109,T121	C2351398
28069279	1072	1079	placebo	T122	C1696465
28069279	1111	1126	severe symptoms	T033	C0436345
28069279	1132	1148	primary endpoint	T130	C2986535
28069279	1164	1172	response	T201	C0521982
28069279	1179	1190	improvement	T077	C2986411
28069279	1196	1204	baseline	T081	C1442488
28069279	1240	1263	severe baseline symptom	T033	C0436345
28069279	1284	1292	pruritus	T184	C0033774
28069279	1293	1298	score	T081	C0449820
28069279	1345	1381	Hamilton Rating Scale for Depression	T170	C0451203
28069279	1400	1420	Fatigue Impact Scale	T170	C2733557
28069279	1448	1464	treatment effect	T080	C0087113
28069279	1489	1500	methodology	T062	C0086912
28069279	1505	1518	rare diseases	T047	C0678236
28069279	1527	1564	generalised estimating equation model	T170	C0282574
28069279	1579	1597	intention-to-treat	T062	C2718028
28069279	1598	1608	population	T098	C1257890
28069279	1624	1636	participants	T098	C0679646
28069279	1649	1658	treatment	T061	C0087111
28069279	1693	1720	non-treatment-related cause	T033	C0243095
28069279	1734	1740	safety	T062	C1705187
28069279	1748	1756	patients	T101	C0030705
28069279	1783	1787	dose	T081	C0870450
28069279	1791	1801	study drug	T062	C0013175
28069279	1808	1813	trial	T062	C0008976
28069279	1833	1871	ClinicalTrials.gov, number NCT00814073	T062	C0008976
28069279	1881	1884	Feb	T080	C3830166
28069279	1899	1903	July	T080	C3829447
28069279	1918	1926	patients	T101	C0030705
28069279	1932	1949	randomly assigned	UnknownType	C0814868
28069279	1953	1962	masitinib	T109,T121	C2351398
28069279	1973	1980	placebo	T122	C1696465
28069279	1995	2000	weeks	T079	C0439230
28069279	2002	2011	masitinib	T109,T121	C2351398
28069279	2016	2031	associated with	T080	C0332281
28069279	2045	2053	response	T201	C0521982
28069279	2070	2086	primary endpoint	T130	C2986535
28069279	2094	2103	responses	T201	C0521982
28069279	2122	2131	responses	T201	C0521982
28069279	2133	2173	weighted generalised estimating equation	T080	C0205556
28069279	2199	2206	placebo	T122	C1696465
28069279	2241	2251	odds ratio	T081	C0028873
28069279	2285	2293	Frequent	T079	C0332183
28069279	2294	2315	severe adverse events	T033	C1519255
28069279	2337	2344	placebo	T122	C1696465
28069279	2351	2360	diarrhoea	T184	C0011991
28069279	2387	2396	masitinib	T109,T121	C2351398
28069279	2397	2402	group	T078	C0441833
28069279	2428	2435	placebo	T122	C1696465
28069279	2436	2441	group	T078	C0441833
28069279	2474	2482	asthenia	T184	C0004093
28069279	2517	2525	frequent	T079	C0332183
28069279	2526	2548	serious adverse events	T033	C1519255
28069279	2554	2563	diarrhoea	T184	C0011991
28069279	2571	2579	patients	T101	C0030705
28069279	2602	2611	urticaria	T047	C0042109
28069279	2639	2655	life-threatening	T033	C2826244
28069279	2656	2666	toxicities	T037	C0600688
28069279	2681	2688	patient	T101	C0030705
28069279	2696	2703	placebo	T122	C1696465
28069279	2704	2709	group	T078	C0441833
28069279	2710	2714	died	T033	C1546956
28069279	2716	2725	unrelated	T080	C1704623
28069279	2729	2744	study treatment	T062	C3161471
28069279	2753	2767	study findings	T033	C0683954
28069279	2782	2791	masitinib	T109,T121	C2351398
28069279	2798	2807	effective	T080	C1704419
28069279	2817	2832	tolerated agent	T121	C1254351
28069279	2841	2850	treatment	T061	C0087111
28069279	2854	2874	severely symptomatic	T033	C0436345
28069279	2875	2883	indolent	T047	C0272203
28069279	2887	2920	smouldering systemic mastocytosis	T191	C3897042